Disclosure Of Interests In Other Entities [Text Block]

Hyloris Pharmaceuticals SA - Filing #5880974

Concept	2024-01-01 to 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31
Disclosure of interests in other entities [text block]	—	—	—	—	—	—	—
Disclosure of interests in subsidiaries [text block]	—	—	—	—	—	—	—
Disclosure of subsidiaries [text block]	6	—	—	—	—	—	—
Disclosure of subsidiaries [abstract]
Disclosure of subsidiaries [line items]
Current assets	—	29,707,000 EUR	—	—	35,308,000 EUR	—	—
Non-current assets	—	11,628,000 EUR	—	—	12,373,000 EUR	—	—
Current liabilities	—	7,162,000 EUR	—	—	6,759,000 EUR	—	—
Non-current liabilities	—	2,030,000 EUR	—	—	1,853,000 EUR	—	—
Revenue	8,458,000 EUR	—	—	2,087,000 EUR	—	—	—
Profit (loss)	6,342,000 EUR	—	—	15,380,000 EUR	—	—	—
Comprehensive income	6,342,000 EUR	—	6,342,000 EUR	15,380,000 EUR	—	15,380,000 EUR	—
Disclosure of interests in associates [text block]	—	—	—	—	—	—	—
Disclosure of associates [text block]	—	—	—	—	—	—	—
Disclosure of associates [abstract]
Disclosure of associates [line items]
Other comprehensive income	- EUR	—	—	- EUR	—	—	—
Investments accounted for using equity method	—	2,748,000 EUR	—	—	3,801,000 EUR	—	—
Disclosure of interests in joint arrangements [text block]	—	—	—	—	—	—	—
Disclosure of joint operations [text block]	3	—	—	—	—	—	—
Disclosure of joint ventures [text block]	—	—	—	—	—	—	—
Disclosure of joint ventures [abstract]
Disclosure of joint ventures [line items]
Cash and cash equivalents	—	23,594,000 EUR	—	—	30,406,000 EUR	—	33,457,000 EUR
Other current financial liabilities	—	3,000,000 EUR	—	—	3,200,000 EUR	—	—
Other non-current financial liabilities	—	368,000 EUR	—	—	344,000 EUR	—	—
Tax expense (income)	- EUR	—	—	- EUR	—	—	—